{"filing":{"accession_number":"0001437749-26-017821","cik":"0001645469","ticker":"MNPR","company_name":"Monopar Therapeutics","form":"8-K","filing_date":"2026-05-19","report_date":null,"primary_document":"mnpr20260513_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926017821/mnpr20260513_8k.htm"},"events":[{"id":10174,"run_id":8920,"accession_number":"0001437749-26-017821","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"Monopar disclosed positive Phase 2 clinical trial results for ALXN1840 in Wilson disease via press release under Item 7.01 (Regulation FD Disclosure). While this is clinical progress material to investors in a biopharmaceutical company, it does not fit the \"earnings_release\" category (which typically covers financial results) and lacks the specificity of other event types. The disclosure of material clinical trial outcomes is a significant corporate event but is best classified as \"other_material\" given the taxonomy's focus on financial and governance events.","company_name":"Monopar Therapeutics","ticker":"MNPR","filing_date":"2026-05-19","form":"8-K","submitted_at":null,"items":[{"id":291,"accession_number":"0001437749-26-017821","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Monopar disclosed positive Phase 2 clinical trial results for ALXN1840 in Wilson disease via press release under Item 7.01 (Regulation FD Disclosure). While this is clinical progress material to investors in a biopharmaceutical company, it does not fit the \"earnings_release\" category (which typically covers financial results) and lacks the specificity of other event types. The disclosure of material clinical trial outcomes is a significant corporate event but is best classified as \"other_material\" given the taxonomy's focus on financial and governance events.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:41:27.734920+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":291,"accession_number":"0001437749-26-017821","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Monopar disclosed positive Phase 2 clinical trial results for ALXN1840 in Wilson disease via press release under Item 7.01 (Regulation FD Disclosure). While this is clinical progress material to investors in a biopharmaceutical company, it does not fit the \"earnings_release\" category (which typically covers financial results) and lacks the specificity of other event types. The disclosure of material clinical trial outcomes is a significant corporate event but is best classified as \"other_material\" given the taxonomy's focus on financial and governance events.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:41:27.734920+00:00","company_name":"Monopar Therapeutics","ticker":"MNPR","filing_date":"2026-05-19"}]}